269 related articles for article (PubMed ID: 19745172)
1. Statin treatment and stroke outcome in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Goldstein LB; Amarenco P; Zivin J; Messig M; Altafullah I; Callahan A; Hennerici M; MacLeod MJ; Sillesen H; Zweifler R; Michael K; Welch A;
Stroke; 2009 Nov; 40(11):3526-31. PubMed ID: 19745172
[TBL] [Abstract][Full Text] [Related]
2. Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Callahan A; Amarenco P; Goldstein LB; Sillesen H; Messig M; Samsa GP; Altafullah I; Ledbetter LY; MacLeod MJ; Scott R; Hennerici M; Zivin JA; Welch KM;
Arch Neurol; 2011 Oct; 68(10):1245-51. PubMed ID: 21670382
[TBL] [Abstract][Full Text] [Related]
3. Effect of high-dose atorvastatin on renal function in subjects with stroke or transient ischemic attack in the SPARCL trial.
Amarenco P; Callahan A; Campese VM; Goldstein LB; Hennerici MG; Messig M; Sillesen H; Welch KM; Wilson DJ; Zivin JA
Stroke; 2014 Oct; 45(10):2974-82. PubMed ID: 25147328
[TBL] [Abstract][Full Text] [Related]
4. Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Sillesen H; Amarenco P; Hennerici MG; Callahan A; Goldstein LB; Zivin J; Messig M; Welch KM;
Stroke; 2008 Dec; 39(12):3297-302. PubMed ID: 18845807
[TBL] [Abstract][Full Text] [Related]
5. Coronary heart disease risk in patients with stroke or transient ischemic attack and no known coronary heart disease: findings from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Amarenco P; Goldstein LB; Sillesen H; Benavente O; Zweifler RM; Callahan A; Hennerici MG; Zivin JA; Welch KM;
Stroke; 2010 Mar; 41(3):426-30. PubMed ID: 20110538
[TBL] [Abstract][Full Text] [Related]
6. Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Amarenco P; Goldstein LB; Callahan A; Sillesen H; Hennerici MG; O'Neill BJ; Rudolph AE; Simunovic L; Zivin JA; Welch KM;
Atherosclerosis; 2009 Jun; 204(2):515-20. PubMed ID: 18962621
[TBL] [Abstract][Full Text] [Related]
7. Low cholesterol, statins and outcomes in patients with first-ever acute ischemic stroke.
Koton S; Molshatzki N; Bornstein NM; Tanne D
Cerebrovasc Dis; 2012; 34(3):213-20. PubMed ID: 23006641
[TBL] [Abstract][Full Text] [Related]
8. The atorvastatin during ischemic stroke study: a pilot randomized controlled trial.
Muscari A; Puddu GM; Santoro N; Serafini C; Cenni A; Rossi V; Zoli M
Clin Neuropharmacol; 2011; 34(4):141-7. PubMed ID: 21677574
[TBL] [Abstract][Full Text] [Related]
9. Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes.
Amarenco P; Benavente O; Goldstein LB; Callahan A; Sillesen H; Hennerici MG; Gilbert S; Rudolph AE; Simunovic L; Zivin JA; Welch KM;
Stroke; 2009 Apr; 40(4):1405-9. PubMed ID: 19228842
[TBL] [Abstract][Full Text] [Related]
10. Atherogenic dyslipidemia and residual cardiovascular risk in statin-treated patients.
Sirimarco G; Labreuche J; Bruckert E; Goldstein LB; Fox KM; Rothwell PM; Amarenco P;
Stroke; 2014 May; 45(5):1429-36. PubMed ID: 24736236
[TBL] [Abstract][Full Text] [Related]
11. High-dose statin therapy for secondary prevention of stroke: stroke prevention by aggressive reduction in cholesterol levels study review.
Schwertz DW; Badellino KO
J Cardiovasc Nurs; 2008; 23(1):8-13. PubMed ID: 18158500
[TBL] [Abstract][Full Text] [Related]
12. Oxidized Phospholipids on Apolipoprotein B-100 and Recurrent Ischemic Events Following Stroke or Transient Ischemic Attack.
Byun YS; Yang X; Bao W; DeMicco D; Laskey R; Witztum JL; Tsimikas S;
J Am Coll Cardiol; 2017 Jan; 69(2):147-158. PubMed ID: 28081824
[TBL] [Abstract][Full Text] [Related]
13. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Amarenco P; Goldstein LB; Szarek M; Sillesen H; Rudolph AE; Callahan A; Hennerici M; Simunovic L; Zivin JA; Welch KM;
Stroke; 2007 Dec; 38(12):3198-204. PubMed ID: 17962589
[TBL] [Abstract][Full Text] [Related]
14. Drug insight: translating evidence on statin therapy into clinical benefits.
Sanossian N; Ovbiagele B
Nat Clin Pract Neurol; 2008 Jan; 4(1):43-9. PubMed ID: 18199996
[TBL] [Abstract][Full Text] [Related]
15. Relative effects of statin therapy on stroke and cardiovascular events in men and women: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study.
Goldstein LB; Amarenco P; Lamonte M; Gilbert S; Messig M; Callahan A; Hennerici M; Sillesen H; Welch KM;
Stroke; 2008 Sep; 39(9):2444-8. PubMed ID: 18617654
[TBL] [Abstract][Full Text] [Related]
16. Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories: The SPARCL Trial.
Szarek M; Amarenco P; Callahan A; DeMicco D; Fayyad R; Goldstein LB; Laskey R; Sillesen H; Welch KM;
J Am Coll Cardiol; 2020 May; 75(17):2110-2118. PubMed ID: 32194196
[TBL] [Abstract][Full Text] [Related]
17. Favorable outcome of ischemic stroke in patients pretreated with statins.
Martí-Fàbregas J; Gomis M; Arboix A; Aleu A; Pagonabarraga J; Belvís R; Cocho D; Roquer J; Rodríguez A; García MD; Molina-Porcel L; Díaz-Manera J; Martí-Vilalta JL
Stroke; 2004 May; 35(5):1117-21. PubMed ID: 15073403
[TBL] [Abstract][Full Text] [Related]
18. [Statins in the secondary prevention of stroke: New evidence from the SPARCL Study].
Castilla-Guerra L; Fernández-Moreno Mdel C; López-Chozas JM
Clin Investig Arterioscler; 2016; 28(4):202-8. PubMed ID: 26150172
[TBL] [Abstract][Full Text] [Related]
19. High-dose atorvastatin and risk of atrial fibrillation in patients with prior stroke or transient ischemic attack: analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Schwartz GG; Chaitman BR; Goldberger JJ; Messig M
Am Heart J; 2011 May; 161(5):993-9. PubMed ID: 21570534
[TBL] [Abstract][Full Text] [Related]
20. Statin therapy and stroke prevention: what was known, what is new and what is next?
Mazighi M; Lavallée PC; Labreuche J; Amarenco P
Curr Opin Lipidol; 2007 Dec; 18(6):622-5. PubMed ID: 17993806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
